PARP Inhibitors in Metastatic Prostate Cancer: Biomarker Testing, Treatment Strategies, and Toxicity Management

In this podcast, experts discuss the evolving role of PARP inhibitors in metastatic prostate cancer, with a focus on the biologic rationale for PARP inhibition in tumors with HRR alterations, the importance of germline and somatic genomic testing, and the clinical evidence supporting PARP inhibitor monotherapy and combinations with ARPI. The discussion highlights data from trials including AMPLITUDE and TALAPRO-3, considers how specific HRR alterations may influence treatment selection across metastatic disease settings, and reviews practical strategies for monitoring and managing adverse events such as anemia and nausea.